You can access any of the podium or poster presentations’ abstracts by searching for it below.
Export this Abstract | Print this Abstract |
Add to my preferred Abstracts list |
My preferred Abstracts list (0) |
Back to Search
Tobramycin clearance in a cystic fibrosis patient on haemodialysis: implications for dosing
- At: Glasgow (Scotland) (2018)
- Type: Poster
- Poster code: POS-PAA-001
- By: BROWN, Catherine (Alfred Health, Pharmacy)
- Co-author(s): Catherine Elizabeth Brown: Pharmacy, Alfred Health, Melbourne, Australia
Vanessa Inserra: Pharmacy, Alfred Health, Melbourne, Australia
Scott Wilson: Renal Medicine, Alfred Health, Melbourne, Australia - Abstract:
Background
In the era of conventional high-flux haemodialysis (HF-HD), standardised dosing practices for tobramycin (or any aminoglycoside) are not established for the dialysis dependent patientMethods
Following a 120mg intravenous dose of tobramycin 5 days prior, a 54 year old male with cystic fibrosis and end-stage renal disease recorded a plasma.. The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress.
Please login
Last update 2 July 2026